申请人:RECORDATI CHEM PHARM
公开号:WO2003106443A1
公开(公告)日:2003-12-24
Compounds of formula (I) (R and R1 are a wide range of substituents,
Q is CO, CHOH or CHOR2, R2 is alkyl, alkenyl, alkynyl or cycloalkyl
group, each of which is optionally substituted, or is alkanoyl, alkanoyoxy,
aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminothiocarbonyl,
alkylaminothiocarbonyl or dialkylaminothiocarbonyl, R3 is H, alkyl,
-alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, each of which is
optionally substituted, n is 1 or 2, A is a bond or a methylene or ethylene group
and R4 is an aryl or heteroaryl group, either of which is optionally
substituted) have affinity for serotoninergic receptors. These compounds
and their enantiomers, diastereoisomers, N-piperazine oxides, polymorphs,
solvates and pharmaceutically acceptable salts are useful in the treatment
of patients with neuromuscular dysfunction of the lower urinary tract and diseases
related to 5-HT1A receptor activity.
化合物的化学式(I)(其中R和R1是一系列取代基,Q为CO、CHOH或CHOR2,R2为烷基、烯基、炔基或环烷基,每个取代基均可选择性地取代,或为烷酰基、烷氧基、氨基甲酰基、烷基氨基甲酰基、二烷基氨基甲酰基、氨基硫代甲酰基、烷基氨基硫代甲酰基或二烷基氨基硫代甲酰基,R3为H、烷基、烯基、炔基、环烷基、芳基或杂环基,每个取代基均可选择性地取代,n为1或2,A为键或亚甲基或乙烯基,R4为芳基或杂芳基,每个均可选择性地取代)具有与5-羟色胺受体的亲和性。这些化合物及其对映异构体、顺反异构体、N-哌嗪氧化物、多晶形、溶剂合物和药学上可接受的盐对治疗患有下尿路神经肌肉功能障碍和与5-HT1A受体活性相关的疾病的患者具有用处。